Literature DB >> 16899320

Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification.

Petr Chytil1, Tomás Etrych, Cestmír Konák, Milada Sírová, Tomás Mrkvan, Blanka Ríhová, Karel Ulbrich.   

Abstract

Various conjugates of anticancer drug doxorubicin (DOX) covalently attached via hydrolytically degradable hydrazone bond to water-soluble N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer drug carriers were synthesized. Three types of precursors containing either positively or negatively charged groups or a hydrophobic substituent were employed. In vitro incubation of the conjugates in buffers showed relative stability at pH 7.4 (modelling blood) and a fast DOX release at pH 5 (modelling intracellular environment). The presence of carboxylic groups in the copolymer structure resulted in an increase in the DOX release rate of 15-20% while no effect of the introduction of positively charged groups was observed if compared with the unmodified conjugate. Self-assembling of the oleoyl groups-containing conjugate led into formation of polymeric micelles with high apparent molecular weight (M(w)=170,000) in aqueous solution and resulted in a decrease in the DOX release rate of approximately 20%. The cytostatic activity of the conjugates tested on several cancer cell lines was comparable with that of free DOX.HCl, depending on the sensitivity of a particular cell line to DOX. All the conjugates showed a much higher antitumour activity in vivo than the free drug tested in mice bearing EL4 T-cell lymphoma and treated using the therapeutic regime of drug administration. The highest activity (100% long-term survivors) exhibited polymer-DOX conjugate containing negatively charged GFLG sequences.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16899320     DOI: 10.1016/j.jconrel.2006.06.028

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  7 in total

1.  Synthesis and characterization of poly(ε-caprolactone)-block-poly[N-(2-hydroxypropyl)methacrylamide] micelles for drug delivery.

Authors:  Stefan G Krimmer; Huaizhong Pan; Jihua Liu; Jiyuan Yang; Jindřich Kopeček
Journal:  Macromol Biosci       Date:  2011-05-12       Impact factor: 4.979

Review 2.  Design of smart HPMA copolymer-based nanomedicines.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

3.  Nanoconjugate based on polymalic acid for tumor targeting.

Authors:  Julia Y Ljubimova; Manabu Fujita; Natalya M Khazenzon; Bong-Seop Lee; Sebastian Wachsmann-Hogiu; Daniel L Farkas; Keith L Black; Eggehard Holler
Journal:  Chem Biol Interact       Date:  2007-02-08       Impact factor: 5.192

Review 4.  Drug delivery to solid tumors by elastin-like polypeptides.

Authors:  Jonathan R McDaniel; Daniel J Callahan; Ashutosh Chilkoti
Journal:  Adv Drug Deliv Rev       Date:  2010-05-27       Impact factor: 15.470

Review 5.  Covalent nano delivery systems for selective imaging and treatment of brain tumors.

Authors:  Julia Y Ljubimova; Tao Sun; Leila Mashouf; Alexander V Ljubimov; Liron L Israel; Vladimir A Ljubimov; Vida Falahatian; Eggehard Holler
Journal:  Adv Drug Deliv Rev       Date:  2017-06-10       Impact factor: 15.470

Review 6.  Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery.

Authors:  Julia Y Ljubimova; Manabu Fujita; Alexander V Ljubimov; Vladimir P Torchilin; Keith L Black; Eggehard Holler
Journal:  Nanomedicine (Lond)       Date:  2008-04       Impact factor: 5.307

7.  Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes.

Authors:  Lingdong Quan; Yijia Zhang; Bart J Crielaard; Anand Dusad; Subodh M Lele; Cristianne J F Rijcken; Josbert M Metselaar; Hana Kostková; Tomáš Etrych; Karel Ulbrich; Fabian Kiessling; Ted R Mikuls; Wim E Hennink; Gert Storm; Twan Lammers; Dong Wang
Journal:  ACS Nano       Date:  2013-12-27       Impact factor: 15.881

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.